Results 211 to 220 of about 58,715 (292)

Molecular Quantification of Fibrogenesis and Macrophage Activation Associate With Clinical Worsening in Patients With Cirrhosis

Liver International Communications, Volume 7, Issue 2, June 2026.
ABSTRACT Knowledge of the potential of biomarkers for monitoring clinical improvement, assessing trajectory or disease progression in advanced chronic liver disease is still insufficient. This study investigated biomarkers of fibrosis and macrophage activation over time in newly diagnosed patients with cirrhosis and their potential association with ...
Emilie Toft Skovgaard, Jens Peter Goetze, Thit Mynster Kronborg, Søren Møller, Henning Grønbæk, Holger Jon Møller, Morten Karsdal, Diana Julie Leeming, Nina Kimer   +8 more
wiley   +1 more source

Rifaximin reduces rehospitalization risk in patients with cirrhosis and overt hepatic encephalopathy. [PDF]

Hepatol Commun
Jesudian AB, Gagnon-Sanschagrin P, Bungay R, Easson K, Bellefleur R, Guérin A, Shah SK, Olujohungbe O.   +7 more
europepmc   +1 more source

Exploring and Targeting the Connection of Iron and Copper Homeostasis to Neurodegenerative Diseases

MedComm, Volume 7, Issue 6, June 2026.
Iron and copper dyshomeostasis, along with their interactions with key intrinsically disordered proteins (e.g., Aβ, tau, α‐synuclein) have a strong implication in the onset and progression of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Prion diseases (PrDs), Huntington's disease (HD), Wilson's disease (WD),
Xin Liu, Lin Jia, Kerong Wu, Mo Chen, Jichao Sun, Chuanbin Yang, Chengchao Xu, Jie Sun, Jigang Wang, Lingyun Dai   +9 more
wiley   +1 more source

Organoids: From Bench to Bedside Applications

MedComm, Volume 7, Issue 6, June 2026.
Organoids, as a groundbreaking biomedical research platform, utilize adult stem cells (ASCs), embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs) as sources. By integrating specific growth and differentiation signals within an extracellular matrix (e.g., Matrigel), organoids guide cells to self‐assemble into three‐dimensional ...
Kelin Li, Rui Cao, Maochen Li, Zichao Tian, Huahao Fan, Bixia Hong, Xiaojuan Liu   +6 more
wiley   +1 more source

Risk prediction models for hepatic encephalopathy in patients with liver cirrhosis: a systematic review and meta-analysis. [PDF]

BMC Gastroenterol
Xiao Z, Li X, Dong S, Zhou F.
europepmc   +1 more source

Bioartificial Livers Developed From Gene‐Edited Pig Hepatocyte Organoids Improve Amino Acid and Lipid Profiles in the Plasma of Patients With Liver Failure

MedComm, Volume 7, Issue 6, June 2026.
A bioartificial liver (BAL) integrating GGTA1‐knockout porcine hepatocytes and R‐spondin1‐overexpressing endothelial organoids was tested using plasma from patients with acute‐on‐chronic liver failure (ACLF). The BAL system actively modulates amino acid and lipid metabolism, enhances detoxification, partially restores overall metabolic balance, and ...
Yuting He, Yang Deng, Xinglong Zhu, Mengyu Gao, Qin Liu, Wanliu Peng, Yanyan Zhou, Lang Bai, Ji Bao   +8 more
wiley   +1 more source

Encephalopathy: Cause, Pathogenesis, and Treatment

MedComm, Volume 7, Issue 6, June 2026.
Various encephalopathies (sepsis‐associated, hepatic, hypoxic–ischemic, diabetic, uremic, toxic) have incompletely elucidated pathogenesis, which severely restricts targeted therapy development. Small molecule drugs show unique multitarget potential but face toxicity, poor blood–brain barrier penetration and unclear specificity.
Shimeng Lv, Xia Zhong, Ruirui Shang, Linghui Kong, Yufei Huang, Yuexiang Ma, Jing Teng, Sheng Wei   +7 more
wiley   +1 more source

S100B protein as a marker of minimal hepatic encephalopathy. [PDF]

Prz Gastroenterol
Pisarek W, Jarmołowicz J, Poniewierka E.   +2 more
europepmc   +1 more source

Hepatic Arterial Infusion Chemotherapy plus either Toripalimab or Sorafenib as First‐line Therapy for Locally Advanced Hepatocellular Carcinoma: A Non‐comparative, Randomized Phase 2 Trial

MedComm, Volume 7, Issue 6, June 2026.
This phase II study explored the efficacy and safety of HAIC plus toripalimab in locally advanced HCC. The primary endpoint was the PFS rate at 6 months. The 6‐month PFS rate was 63.9% in the TorHAIC group and 61.1% in the SoraHAIC group. Treatment with the TorHAIC regimen resulted in a median OS of 20.9 months and a median PFS of 9.1 months.
Zhicheng Lai, Aojie Ge, Hanyue Ouyang, Zichao Wu, Yexing Huang, Qijiong Li, Li Xu, Binkui Li, Minshan Chen, Dongsheng Wen, Anna Kan, Ming Shi, Minke He   +12 more
wiley   +1 more source

Secondary Prophylaxis of Hepatic encephalopathy in Liver cirrhosis: Rifixamine plus Probiotics vs. Rifixamine alone. [PDF]

Pak J Med Sci
Shahzad K, Sarwar S, Saeed S, Umer A.
europepmc   +1 more source